Ubiquitous Chromatin Opening Element technology will be used in research programs.

Astellas Pharma obtained rights to use Millipore’s UCOE™ (ubiquitous chromatin opening element) technology in its research programs. The worldwide, nonexclusive license will allow the company to produce its drug targets such as antibodies in mammalian cells by generating higher protein yields.

Millipore’s UCOE technology can be used to generate proteins at a small scale for drug discovery and research as well as to identifying stable and highly productive cell lines suitable for larger scale manufacturing.

It helps biopharmaceutical companies identify which cells will be the most effective in producing proteins during large-scale manufacturing. By isolating these stable and highly productive cell lines, biopharmaceutical manufacturers can improve the yield and consistency of their production processes.

Previous articleResearchers Elucidate Role of Tat Protein in Development of Dementia in HIV Patients
Next articleAzur Pharma Acquires U.S. Rights to BioSante’s Estrogen Gel for $3.3M